Royalty Pharma
RPRX
56.76
+0.32
+0.57%
Royalty Pharma
US · RPRX
#759 by market cap
Listed 2020
56.76
+0.32
+0.57%
Live - 5344 symbols - heartbeat 306s ago
· 2026-10-08 07:37
Pre-market
56.57
-0.33%
After-hours
56.76
0.00%
- Market cap
- 25.27B
- P/E (TTM)i
- 30.52
- P/Bi
- 3.70
- EPSi
- 1.78
- Div yieldi
- 1.60%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on RPRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.14, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.06% YoY
Margins
- Operating margin
- 65.58%
- Net margin
- 32.42%
Key ratios & quality
- Enterprise valuei
- 32.73B
- PEG ratioi
- 0.19
- Altman Z-Scorei
- 2.14
PEG uses trailing P/E against the 3-year net income growth rate (162.07%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.79B | 1.81B | -- | -- | 2.24B | 2.35B | 2.26B | 2.38B |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 61.91M | 103.44M | 181.72M | 182.83M | 227.30M | 249.75M | 236.67M | 573.48M |
| Research & development | 392.61M | 83.04M | 26.29M | 200.08M | 177.11M | 52.00M | 2.00M | 452.00M |
| Operating profit | 1.36B | 2.62B | 1.66B | 1.43B | 922.89M | 1.49B | 1.29B | 1.56B |
| Pretax profit | 1.52B | 2.46B | 1.70B | 1.24B | 230.06M | 1.70B | 1.33B | 1.32B |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 1.52B | 2.46B | 1.70B | 1.24B | 230.06M | 1.70B | 1.33B | 1.32B |
| Basic EPS | 4 | 7 | 1 | 1 | 0 | 3 | 2 | 2 |
| Diluted EPS | 3.89 | 6.63 | 1.32 | 1.49 | 0.10 | 2.53 | 1.91 | 1.78 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | 578.67M | 609.29M | 621.99M | -- | 674.14M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 110.71M | 179.77M | 118.73M | 164.27M | 159.49M | 161.89M |
| Research & development | 50.50M | 300.50M | 50.50M | 50.50M | 39.79M | 97.85M |
| Operating profit | 534.18M | 209.80M | 427.16M | 388.38M | 632.48M | 133.12M |
| Pretax profit | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M |
| Basic EPS | 1 | 0 | 1 | 0 | 1 | 0 |
| Diluted EPS | 0.55 | 0.07 | 0.67 | 0.38 | 0.67 | 0.04 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.61B | 832.07M | 2.70B | 2.88B | 2.55B | 1.27B | 1.80B | 1.53B |
| Cash & ST investments | 2.39B | 793.21M | 2.65B | 2.80B | 2.43B | 1.23B | 1.77B | 1.49B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 11.37B | 12.45B | 16.02B | 17.52B | 16.81B | 16.38B | 18.22B | 19.62B |
| Total current liabilities | 580.17M | 333.42M | 307.89M | 171.25M | 1.17B | 161.38M | 1.25B | 636.21M |
| Short-term debt | 281.44M | 281.98M | -- | -- | 997.51M | -- | 997.77M | 380.00M |
| Long-term debt | 6.24B | 5.96B | 5.82B | 7.10B | 6.12B | 6.14B | 6.61B | 8.57B |
| Total liabilities | 6,818,068,000.00 | 6,308,457,000.00 | 6,124,471,000.00 | 7,267,320,000.00 | 7,288,093,000.00 | 6,297,562,000.00 | 7,880,349,000.00 | 9,905,841,000.00 |
| Total equity | 4.55B | 6.14B | 9.90B | 10.25B | 9.53B | 10.08B | 10.34B | 9.71B |
| Retained earnings | 1.22B | 2.83B | 1.92B | 2.26B | 1.96B | 2.52B | 2.85B | 2.36B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.84B | 1.52B | 1.85B | 1.53B | 1.43B | 1.76B |
| Cash & ST investments | 1.82B | 1.49B | 1.82B | 1.49B | 1.39B | 1.73B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 17.61B | 18.32B | 19.35B | 19.62B | 19.82B | 19.82B |
| Total current liabilities | 1.18B | 1.21B | 530.80M | 636.21M | 535.68M | 630.93M |
| Short-term debt | 998.61M | 999.44M | 380.00M | 380.00M | 380.00M | 380.00M |
| Long-term debt | 6.62B | 7.00B | 8.57B | 8.57B | 8.58B | 8.58B |
| Total liabilities | 7,819,599,000.00 | 8,820,060,000.00 | 9,726,419,000.00 | 9,905,841,000.00 | 9,878,582,000.00 | 10,034,057,000.00 |
| Total equity | 9.79B | 9.50B | 9.62B | 9.71B | 9.94B | 9.79B |
| Retained earnings | 2.48B | 2.22B | 2.30B | 2.36B | 2.51B | 2.46B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.62B | 1.67B | 2.03B | 2.02B | 2.14B | 2.99B | 2.77B | 2.49B |
| Depreciation & amortization | 33.27M | 23.92M | 23.06M | 23.00M | 5.67M | 0 | 0 | 3.85M |
| Free cash flow | 1.62B | 1.67B | 2.03B | 2.02B | 2.14B | 2.99B | 2.77B | 2.49B |
| Dividends paid | -814.36M | -739.28M | -397.84M | -285.18M | -333.32M | -358.33M | -376.47M | -378.25M |
| Stock buybacks / issuance | 0 | -4.27M | 1.91B | 0 | 0 | -304.76M | -229.65M | -1.23B |
| Ending cash balance | 1.92B | 246.20M | 1.01B | 1.54B | 1.71B | 477.01M | 929.03M | 618.70M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 596.08M | 363.98M | 702.62M | 827.15M | 718.23M | 728.46M |
| Depreciation & amortization | 0 | 1.38M | 1.28M | 1.20M | 1.17M | 1.29M |
| Free cash flow | 596.08M | 363.98M | 702.62M | 827.15M | 718.23M | 728.46M |
| Dividends paid | -95.36M | -93.24M | -95.31M | -94.34M | -104.49M | -104.92M |
| Stock buybacks / issuance | -708.78M | -291.57M | -146.49M | -80.54M | -50.10M | -44.64M |
| Ending cash balance | 1.09B | 631.91M | 938.94M | 618.70M | 586.40M | 811.99M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 30.70 | 22.41 | 9.07 | 11.70 | 0.75 | 25.14 | 12.75 | 11.49 |
| ROA %i | 12.12 | 9.97 | 3.48 | 3.70 | 0.25 | 9.20 | 4.96 | 4.07 |
| ROIC %i | 14.84 | 12.28 | 5.50 | 6.23 | 1.15 | 13.46 | 7.35 | 6.97 |
| 5-year avg ROE %i | -- | -- | -- | -- | 19.31 | 16.91 | 10.59 | 11.07 |
| EBIT margin %i | 100.16 | 150.47 | 87.59 | 61.47 | 18.69 | 80.15 | 68.76 | 68.62 |
| FCF / sales %i | 90.16 | 91.90 | 95.87 | 88.12 | 95.83 | 126.89 | 122.33 | 104.69 |
| Current ratioi | 4.50 | 2.50 | 8.76 | 16.81 | 2.19 | 7.90 | 1.44 | 2.40 |
| Quick ratioi | 4.45 | 2.50 | 8.73 | 16.77 | 2.11 | 7.78 | 1.43 | 2.39 |
| Debt / assetsi | 57.34 | 50.11 | 36.31 | 40.51 | 42.33 | 37.45 | 41.77 | 45.62 |
| LT debt / equityi | 138.98 | 97.55 | 120.71 | 122.84 | 108.72 | 94.01 | 95.22 | 132.33 |
| Interest coveragei | 6.42 | 10.16 | 11.84 | 8.47 | 2.22 | 10.08 | 6.90 | 5.30 |
| Revenue CAGR (3Y) %i | -- | -- | 9.92 | 8.45 | 7.24 | 3.52 | -0.38 | 2.06 |
| Net income CAGR (3Y) %i | -- | -- | -6.94 | -23.38 | -73.68 | 5.19 | 11.50 | 162.07 |
| FCF CAGR (3Y) %i | -- | -- | 12.78 | 7.63 | 8.74 | 13.66 | 11.13 | 5.11 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 16.57 | 15.92 | 11.52 | 11.49 | 12.17 | 12.32 |
| ROA %i | 6.48 | 5.67 | 4.09 | 4.07 | 4.42 | 4.26 |
| ROIC %i | 9.22 | 8.43 | 6.76 | 6.97 | 7.52 | 7.61 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 89.01 | 83.76 | 67.32 | 68.62 | 69.42 | 67.35 |
| FCF / sales %i | 119.28 | 104.38 | 102.36 | 104.69 | 107.03 | 117.37 |
| Current ratioi | 1.56 | 1.26 | 3.48 | 2.40 | 2.66 | 2.80 |
| Quick ratioi | 1.56 | 1.26 | 3.47 | 2.39 | 2.64 | 2.79 |
| Debt / assetsi | 43.26 | 43.67 | 46.24 | 45.62 | 45.20 | 45.22 |
| LT debt / equityi | 98.96 | 110.32 | 133.54 | 132.33 | 124.50 | 125.60 |
| Interest coveragei | 8.17 | 7.25 | 5.66 | 5.30 | 5.04 | 4.73 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Cystic fibrosis franchise is the largest reported line at 31.79% of revenue, across 8 reported segments.
- No single line clears half of revenue; Other products is next at 27.48%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Cystic fibrosis franchise31.79%
Other products27.48%
Tremfya9.76%
Evrysdi8.72%
Voranigo6.60%
Trelegy6.03%
Other royalty income and revenues5.36%
TYSABRI4.25%
Quote time 2026-10-08 07:37:27 · For reference only, not investment advice and not tailored to your situation.